Human monoclonal antibody specific for the F protein of respiratory syncytial virus (RSV)
US9340604B1 · kind B1 · utility
Assignee
Inventors
Key dates
| Filing date | Oct 29, 2014 |
| Grant date | May 17, 2016 |
| Priority date | — |
| Expiry date | Oct 29, 2034 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/92
- WIPO fieldBiotechnology
- WIPO sectorChemistry
Abstract
This invention is directed to an antibody construct or fragment thereof derived from an RSV-infected human, such that the antibody construct binds with specificity to RSV fusion protein antigenic region II/A with an affinity of greater than 1×10−9 M. Preferably, the antibody construct is capable of neutralizing RSV strains, including at least one RSV strain that is resistant to palivizumab. The invention further relates to nucleic acids encoding the antibody construct or portions thereof, and cell lines expressing the antibody. This invention further relates to methods for producing said antibody construct, and to the use of said antibody construct for treating or preventing infection of a patient by RSV having a normal or mutated version of F protein.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.